Reprise Biomedical

About:

Reprise Biomedical focuses on the development and commercialization of biological medical devices.

Website: http://www.reprisebio.com/

Twitter/X: RepriseBio

Description:

Reprise Biomedical is a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology that supports cellular integration. Reprise was created in connection with a spin-off from Miromatrix Medical Inc. in June 2019. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, commercially available medical devices – MIROMESH Biologic Matrix and MIRODERM® Biologic Wound Matrix – as well as all acellular medical devices in development. MIROMESH and MIRODERM are derived via perfusion decellularization of the highly vascularized porcine liver. A non-crosslinked surgical mesh, MIROMESH comes in a variety of sizes suited for hernia repair applications. MIRODERM is indicated for the management of wounds, including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds.

Total Funding Amount:

$40.8M

Headquarters Location:

Plymouth, Minnesota, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)reprisebio.com

Founders:

Howard Root

Number of Employees:

11-50

Last Funding Date:

2023-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai